EKTA.B

48.48

-3.62%↓

EKTA.B

48.48

-3.62%↓

EKTA.B

48.48

-3.62%↓

EKTA.B

48.48

-3.62%↓

EKTA.B

48.48

-3.62%↓

Search

Orexo AB

Aperta

14.66 2.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14.14

Massimo

14.66

Metriche Chiave

By Trading Economics

Entrata

-76M

-98M

Vendite

24M

160M

EPS

-3.37

Margine di Profitto

-61.135

Dipendenti

110

EBITDA

34M

33M

Dividendi

By Dow Jones

Utili prossimi

6 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

501M

Apertura precedente

11.71

Chiusura precedente

14.66

Orexo AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2025, 23:04 UTC

Notizie principali

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

I principali Market Mover

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr 2025, 23:43 UTC

Discorsi di Mercato

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Discorsi di Mercato

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Notizie principali
Utili

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Discorsi di Mercato

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Notizie principali

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Discorsi di Mercato

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Discorsi di Mercato

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Discorsi di Mercato

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Notizie principali

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Discorsi di Mercato

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Discorsi di Mercato

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Discorsi di Mercato

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr 2025, 17:55 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Orexo AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.